Infectious Diseases from Nature: Mechanisms of Viral Emergence and Persistence
Editat de C. J. Peters, Charles H. Calisheren Limba Engleză Paperback – 27 sep 2005
Preț: 1182.47 lei
Preț vechi: 1442.05 lei
-18% Nou
Puncte Express: 1774
Preț estimativ în valută:
209.21€ • 243.73$ • 182.69£
209.21€ • 243.73$ • 182.69£
Carte tipărită la comandă
Livrare economică 19 ianuarie-02 februarie 26
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9783211243343
ISBN-10: 3211243348
Pagini: 224
Ilustrații: VIII, 216 p. 41 illus. in color.
Dimensiuni: 216 x 279 x 19 mm
Greutate: 0.81 kg
Ediția:2005
Editura: SPRINGER VIENNA
Colecția Springer
Locul publicării:Vienna, Austria
ISBN-10: 3211243348
Pagini: 224
Ilustrații: VIII, 216 p. 41 illus. in color.
Dimensiuni: 216 x 279 x 19 mm
Greutate: 0.81 kg
Ediția:2005
Editura: SPRINGER VIENNA
Colecția Springer
Locul publicării:Vienna, Austria
Public țintă
ResearchCuprins
Comments on the life and contributions of Robert E. Shope.- Virus perpetuation in populations: biological variables that determine persistence or eradication.- The virus-immunity ecosystem.- Host range, amplification and arboviral disease emergence.- Regulation of Rodent-Borne viruses in the natural host: implications for human disease.- Population dynamics of RNA viruses: the essential contribution of mutant spectra.- Control of arbovirus diseases: is the vector the weak link?.- Pathogenesis of Rift Valley fever virus in mosquitoes — tracheal conduits & the basal lamina as an extra-cellular barrier.- The virulence of the 1918 pandemic influenza virus: unraveling the enigma.- The spread of the H5N1 bird flu epidemic in Asia in 2004.- Transient or occult HIV infections may occur more frequently than progressive infections: changing the paradigm about HIV persistence.- Ehrlichia under our noses and no one notices.- The role of reverse genetics systems in determining filovirus pathogenicity.- Structural biology of old world and new world alphaviruses.- Species barriers in prion diseases — brief review.- Academic science and the business of vaccines.- Emerging infectious diseases: the public’s view of the problem and what should be expected from the public health community.